drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR-T)
drug_description
Allogeneic donor-derived T cells genetically modified to express a chimeric antigen receptor targeting CD19 on B-lineage leukemia cells; administered as a bridge to allo-HSCT to mediate antigen-specific cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells are genetically engineered to express a CD19-specific chimeric antigen receptor. Upon binding CD19 on B-lineage leukemia cells, CAR signaling (CD3ΞΆ with costimulatory domains) activates the T cells, inducing proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD19+ malignant cells; used as a bridge to allo-HSCT.
drug_name
Donor-derived CD19 CAR-T cell therapy
nct_id_drug_ref
NCT06326008